Shahin Behroyan was named Chief Executive Officer of iSpecimen Inc. As of November 6, 2026, iSpecimen Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on August 31, 2026, naming 1 appointment (Form 8-K, August 31, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like iSpecimen Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
iSpecimen Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-08-31. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as iSpecimen Inc. files it.
Also on the record for iSpecimen Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 7, 2026 | IPO filing, Form 424B4 | $1.3 a share | IPO filings | Source |
| July 17, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| July 6, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| June 24, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| December 19, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| October 6, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| September 8, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| August 25, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| August 20, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| July 25, 2025 | IPO filing, Form 424B4 | $0.7 a share | IPO filings | Source |
| July 8, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| June 27, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
Selling to them or working with them? See who runs iSpecimen Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on iSpecimen Inc. and the records around it.
iSpecimen Inc. elsewhere on the record
- IPO filing Aug 2026
- Who owns it
Watch iSpecimen Inc.
Get an email when iSpecimen Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on iSpecimen Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on iSpecimen Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on iSpecimen Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 17 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-31 | In | Chief Executive Officer | 8-K, 2026-08-31 |
Who leads iSpecimen Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Shahin Behroyan, appointed (filed 2026-08-31).
New leaders reset buying decisions — get the Full Report on iSpecimen Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at iSpecimen Inc., with the record behind each one.
Find candidates like Chief Executive Officer at iSpecimen Inc.Every change, in the filing's words
Appointed: Shahin Behroyan, Chief Executive Officer
On August 26, 2026, the Board appointed Shahin Behroyan as Chief Executive Officer of the Company, effective immediately.
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers.
- Departure of Chief Executive Officer On August 26, 2026, Katharyn Field informed the Board of Directors (the "Board") of iSpecimen Inc. (the "Company") of her decision to transition from her role as Chief Executive Officer.
- Ms. Field's departure as Chief Executive Officer was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
- Ms. Field will continue to support the Company in an internal advisory and consulting capacity.
- Mr. Behroyan, age 39, is a Vancouver-based entrepreneur and business leader with more than two decades of experience spanning investments, consumer packaged goods, healthcare and wellness, politics, and market research.
- Mr. Behroyan has experience with billions of dollars in aggregate transaction value over the course of his career and a significant history of working with multinational companies.
- Mr. Behroyan also has broad experience with emerging growth companies, where he played a central role in building companies and securing national retail distribution across Canada, helping drive brand growth from pre-revenue to millions of dollars in sales.
- Mr. Behroyan has extensive experience in political organizing and fundraising, including work for former British Columbia Premier Gordon Campbell.
Tools for this story
Each opens in a new tab, filled in for iSpecimen Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.